Clinical trials: Malignant Colorectal Neoplasm
Colon Cancer
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule.
- Trial name
- NCT05709249
- Testing
- XLJDOD compound granule
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Adult Liver Carcinoma, Breast Carcinoma
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
This randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. Heating tumor cells to several degrees above normal body temperature may kill tumor cells.
- Conditions
- Adult Liver Carcinoma, Breast Carcinoma, Colon Carcinoma, Kidney Neoplasm
- Trial name
- NCT01896778
- Testing
- Hyperthermia Treatment, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Colon Cancer, Rectal Cancer
Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy
The investigators' null hypothesis is that a withdrawal time of 9 to 10 minutes is non-inferior to a withdrawal time of 12 minutes or greater.
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- NCT05018325
- Testing
- Colonoscopy with 6 minute withdrawal, Colonoscopy 9 minute withdrawal, Colonoscopy 12 minute withdrawal
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Colon Cancer
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Metformin is drug that is normally used to treat people with diabetes. New research has discovered that metformin may also kill cancer stem cells.
- Trial name
- NCT01440127
- Testing
- Metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tufts Medical Center
Colorectal Cancer
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00025142
- Testing
- FOLFOX regimen, fluorouracil, gefitinib
- Where
- United States
- Sponsor
- Stanford University
Colorectal Cancer
Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants
RATIONALE: Evaluating the knowledge and attitudes of healthy participants toward a new diet and gene test for colorectal cancer risk may help doctors improve acceptance of colorectal cancer screening.
- Trial name
- NCT00087360
- Testing
- counseling intervention, physiologic testing, evaluation of cancer risk factors
- Where
- 4 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumor Cells and Tumor Markers in Peritoneal Cavity
Intra-peritoneal Environmental Changes Following Surgery
The investigators hypothesize that the presence of tumor cells and tumor markers in peritoneal cavity are indicative for peritoneal spread during surgery, and may serve as early markers for systemic and/or intra-peritoneal…
- Trial name
- CRC (NCT02102074)
- Where
- 2 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Meir Medical Center
Colon Cancer, MSS/pMMR
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
This is a single-arm, exploratory study enrolling participants with resectable stage III pMMR/MSS colon cancer. Eligible participants who provide written informed consent will receive four cycles of neoadjuvant treatment with…
- Conditions
- Colon Cancer, MSS/pMMR, QL1706
- Trial name
- NCT07156682
- Testing
- QL1706, XELOX
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Qilu Hospital of Shandong University
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Breast Cancer, Colon Cancer
Endogenous Mechanisms of Inactivation of the Endothelium Tumor
The role of immunity in the development of cancers, and the associated escape mechanisms, have attracted renewed interest since the publication of tests testing immunological checkpoint inhibitors.
- Trial name
- BreastIls (NCT03667612)
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Oscar Lambret
Colon Cancer
Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
The purpose of this study is to explore the clinical outcomes of indocyanine green fluorescence using in laparoscopic radical right hemicolectomy for right colon cancer（T1-T4a N+ M0）
- Trial name
- NCT06485609
- Testing
- radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-sen University
Colon Cancer, Chemotherapeutic-Induced Anemia
Intravenous Iron Infusion on Chemotherapy-induced Anemia
FOLFOX, the first-line regimen based on 5-FU and oxaliplatin, is adjuvant chemotherapy for pathologic stage II/III colorectal cancer patients.
- Trial name
- NCT05299411
- Testing
- iron (isomaltoside), Dried Ferrous Sulfate
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449163
- Testing
- Bevacizumab, Floxuridine, Irinotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Colon Cancer
Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)
Background Patients with metastatic colorectal cancer who have progressed after treatment with oxaliplatin- and irinotecan-based chemotherapy, as well as anti-EGFR monoclonal antibodies (cetuximab or panitumumab) according to RAS…
- Trial name
- FIRST-K (NCT07510932)
- Testing
- Fruquintinib
- Volunteers
- 88 people
- Sponsor
- Korea University Anam Hospital
Cancer of Colon, Anesthesia
Anesthesia and Cancer Study: Colon Cancer
This study investigates the influence of type of anesthesia on survival and recurrence rate in patients receiving colon cancer surgery. The participants will be allocated to either the TIVA group and the inhalation group.
- Trial name
- NCT04259398
- Testing
- Propofol, Sevoflurane
- Where
- 2 sites in South Korea
- Volunteers
- 797 people
- Sponsor
- Seoul National University Hospital
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
Colon Cancer
Cancer Control Following Polypectomy
This study evaluates strategies for the surveillance of post-polypectomy patients for the control of bladder cancer
- Trial name
- NCT00591279
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Carcinoma
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e.
- Trial name
- NICHE (NCT03026140)
- Testing
- Nivolumab, Ipilimumab, Celecoxib 200mg
- Where
- 6 sites in Netherlands
- Volunteers
- 353 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site)…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Trial name
- NCT05803382
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 22 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.